Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.

ABSTRACT:

Background

The symptom severity of a substantial group of schizophrenia patients (30-40%) does not improve through pharmacotherapy with antipsychotic medication, indicating a clear need for new treatment options to improve schizophrenia outcome. Meta-analyses, genetic studies, randomized controlled trials, and post-mortem studies suggest that immune dysregulation plays a role in the pathophysiology of schizophrenia. Some anti-inflammatory drugs have shown beneficial effects on the symptom severity of schizophrenia patients. Corticosteroids are effective in various chronic inflammatory and autoimmune disorders. Prednisolone, a potent glucocorticosteroid, has minor mineral-corticosteroid potencies and can adequately pass the blood-brain barrier and its side effects and safety profile

SUBMITTER: Nasib LG 

PROVIDER: S-EPMC7278136 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature